Johns Hopkins University psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Johns Hopkins University is listed with 32 registered studies counted here, in Baltimore, United States. By compound: 29 psilocybin, 1 MDMA, 2 LSD, 1 DMT, 1 5-MeO-DMT, 1 ketamine and 1 ibogaine. By registry status: 11 recruiting, 1 not yet recruiting, 3 active, not recruiting, 13 completed and 4 withdrawn. By phase: 4 early phase 1, 20 phase 1, 7 phase 2 and 1 not applicable. Reported start years run from 2007 (earliest) to 2027 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 32 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 29 |
| MDMA | 1 |
| LSD | 2 |
| DMT | 1 |
| 5-MeO-DMT | 1 |
| Ketamine | 1 |
| Ibogaine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 11 | 34% |
| Not yet recruiting | 1 | 3% |
| Active, not recruiting | 3 | 9% |
| Completed | 13 | 41% |
| Withdrawn | 4 | 13% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 4 | 13% |
| Phase 1 | 20 | 63% |
| Phase 2 | 7 | 22% |
| Not applicable | 1 | 3% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | NCT06005662 | Withdrawn | Phase 2 | 2027-04-01 | Psilocybin |
| Shortened LSD Intervention for Major Depressive Disorder | NCT07503002 | Not yet recruiting | Phase 1 | 2026-07-01 | LSD |
| Psilocybin Efficacy With or Without Pimavanserin Pretreatment | NCT07610135 | Recruiting | Phase 1 | 2026-07-01 | Psilocybin |
| Psilocybin Administration With 5-HT1a Blockade | NCT07565493 | Recruiting | Early Phase 1 | 2026-06-15 | Psilocybin |
| Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability | NCT07053917 | Recruiting | Phase 1 | 2026-02-09 | Psilocybin, LSD |
| Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) | NCT06989957 | Recruiting | Phase 1 | 2025-09-17 | Psilocybin, MDMA |
| Trifecta Research Study | NCT06810765 | Withdrawn | Phase 2 | 2025-09-01 | DMT, 5-MeO-DMT, Ibogaine |
| PRoMiSS: Psilocybin and the Role of Music in Set and Setting | NCT07180108 | Recruiting | Phase 1 | 2025-08-12 | Psilocybin |
| Psilocybin Brain Stimulation and Imaging Pilot Study | NCT06835699 | Completed | Phase 1 | 2025-04-18 | Psilocybin |
| Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | NCT06656702 | Recruiting | Early Phase 1 | 2025-04-09 | Psilocybin |
| Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder | NCT05562973 | Withdrawn | Phase 1 | 2025-01-01 | Psilocybin |
| Safety for Home Administration of Microdose Psilocybin Use | NCT06450210 | Completed | Phase 1 | 2024-12-06 | Psilocybin |
| Psilocybin-assisted Treatment for Cannabis Use Disorder | NCT06660381 | Recruiting | Phase 1 | 2024-11-08 | Psilocybin |
| A Study of Psilocybin for PTSD | NCT06407635 | Active, not recruiting | Phase 1 | 2024-06-07 | Psilocybin |
| Psilocybin in Chronic Low Back Pain and Depression | NCT06355414 | Recruiting | Phase 1 | 2024-04-22 | Psilocybin |
| Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | NCT06067737 | Recruiting | Phase 2 | 2024-02-08 | Psilocybin |
| Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use | NCT05242029 | Withdrawn | Phase 2 | 2023-12-01 | Psilocybin |
| Effects of Psilocybin in Obsessive Compulsive Disorder | NCT05546658 | Active, not recruiting | Early Phase 1 | 2022-11-28 | Psilocybin |
| Effects of Psilocybin in Post-Treatment Lyme Disease | NCT05305105 | Completed | Phase 1 | 2022-07-01 | Psilocybin |
| Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought | NCT05301608 | Recruiting | Phase 1 | 2022-03-03 | Psilocybin |
| Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder | NCT04620759 | Active, not recruiting | Phase 2 | 2021-04-14 | Psilocybin |
| Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | NCT04123314 | Recruiting | Early Phase 1 | 2021-03-24 | Psilocybin |
| Effects of Psilocybin in Anorexia Nervosa | NCT04052568 | Completed | Phase 1 | 2019-08-26 | Psilocybin |
| Ketamine for Treatment of MS Fatigue | NCT03500289 | Completed | Phase 1 | 2018-08-10 | Ketamine |
| Effects of Psilocybin in Major Depressive Disorder | NCT03181529 | Completed | Phase 2 | 2017-08-10 | Psilocybin |
| Persisting Effects of Psilocybin | NCT02971605 | Completed | Phase 1 | 2017-07-01 | Psilocybin |
| Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion | NCT02243813 | Completed | Phase 1 | 2015-03-01 | Psilocybin |
| Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators | NCT02145091 | Completed | Phase 1 | 2014-05-01 | Psilocybin |
| Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators | NCT01988311 | Completed | Phase 1 | 2013-05-01 | Psilocybin |
| Psilocybin and Spiritual Practice | NCT00802282 | Completed | Phase 1 | 2009-08-01 | Psilocybin |
| Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study | NCT01943994 | Completed | Not applicable | 2008-09-01 | Psilocybin |
| Psychopharmacology of Psilocybin in Cancer Patients | NCT00465595 | Completed | Phase 2 | 2007-04-01 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ketamine | Ibogaine